Clinical Trials
8 trialsNCT01868451 2026-06-04
Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT07624838 2026-06-03
Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in Spain
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Recruiting
NCT04685616 2026-06-02
RADAR
University College, London
Phase 3 Recruiting
NCT01476410 2026-05-22
Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma
Northwestern University
Phase 2 Completed
NCT07013565 2026-05-20
ACCELERATE
New York Medical College
Phase 2 Recruiting
NCT03007030 2026-05-15
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT01703949 2026-05-12
Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma
University of Washington
Phase 2 Active not recruiting
NCT01920932 2026-05-06
Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma
St. Jude Children's Research Hospital
Phase 2 Active not recruiting